Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
L.A. Barrera and G.C. Galindo, ‘Ethical aspects on rare diseases’, Adv Exp Med Biol 686 (2010) 493-511.
J.E. Davies, S. Neidle and D.G. Taylor, ‘Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?’, Br J Cancer 106(1) (2012) 14-17.
G.S. Ginsburg and J.J. McCarthy, ‘Personalized medicine: revolutionizing drug discovery and patient care’, Trends in Biotechnology 19(12) (2001) 491-496.
M. Herder, ‘When everyone is an orphan: Against adopting a US-styled orphan drug policy in Canada’, Accountability in Research-Policies and Quality Assurance 20(4) (2013) 227-269.
A. Montserrat Moliner and J. Waligora, ‘The European union policy in the field of rare diseases’, Public Health Genomics 16(6) (2013) 268-277.
A. Paturel, ‘Too Rare for Research? People with rare diseases often experience significant delays in diagnosis and access to few, if any, treatment options’, Neurology Now 8(2) (2012) 29-33.
All Time | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 231 | 30 | 1 |
Full Text Views | 135 | 5 | 0 |
PDF Views & Downloads | 19 | 7 | 0 |
All Time | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 231 | 30 | 1 |
Full Text Views | 135 | 5 | 0 |
PDF Views & Downloads | 19 | 7 | 0 |